Education
About Us
Working with TipRanks
Follow Us
STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Total Valuation
STRATEC Biomedical has a market cap or net worth of €297.21M. The enterprise value is €654.98M.
Market Cap€297.21M
Enterprise Value€654.98M
Share Statistics
STRATEC Biomedical has 12,157,841 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,157,841
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
STRATEC Biomedical’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 4.21%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)4.21%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee179.15K
Profits Per Employee8.94K
Employee Count1,462
Asset Turnover0.56
Inventory Turnover1.38
Valuation Ratios
The current PE Ratio of STRATEC Biomedical is 42.37. STRATEC Biomedical’s PEG ratio is -0.76.
PE Ratio42.37
PS Ratio0.00
PB Ratio2.37
Price to Fair Value2.37
Price to FCF276.71
Price to Operating Cash Flow28.50
PEG Ratio-0.76
Income Statement
In the last 12 months, STRATEC Biomedical had revenue of 261.91M and earned 13.07M in profits. Earnings per share was 1.07.
Revenue261.91M
Gross Profit64.84M
Operating Income25.43M
Pretax Income18.23M
Net Income13.07M
EBITDA39.82M
Earnings Per Share (EPS)1.07
Cash Flow
In the last 12 months, operating cash flow was 34.15M and capital expenditures -15.78M, giving a free cash flow of 18.37M billion.
Operating Cash Flow34.15M
Free Cash Flow18.37M
Free Cash Flow per Share1.51
Dividends & Yields
STRATEC Biomedical pays an annual dividend of €0.55, resulting in a dividend yield of 2.27%
Dividend Per Share€0.55
Dividend Yield2.27%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.15
52-Week Price Change-42.49%
50-Day Moving Average25.41
200-Day Moving Average33.41
Relative Strength Index (RSI)48.25
Average Volume (3m)19.22K
Important Dates
STRATEC Biomedical upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateOct 25, 2024
Next Earnings DateMay 19, 2025
Ex-Dividend DateMay 20, 2024
Financial Position
STRATEC Biomedical as a current ratio of 2.57, with Debt / Equity ratio of 66.97%
Current Ratio2.57
Quick Ratio1.09
Debt to Market Cap0.23
Net Debt to EBITDA2.71
Interest Coverage Ratio6.37
Taxes
In the past 12 months, STRATEC Biomedical has paid 5.16M in taxes.
Income Tax5.16M
Effective Tax Rate0.28
Enterprise Valuation
STRATEC Biomedical EV to EBITDA ratio is 16.61, with an EV/FCF ratio of 330.61.
EV to Sales2.53
EV to EBITDA16.61
EV to Free Cash Flow330.61
EV to Operating Cash Flow34.06
Balance Sheet
STRATEC Biomedical has €35.13M in cash and marketable securities with €62.51M in debt, giving a net cash position of €117.40M billion.
Cash & Marketable Securities€35.13M
Total Debt€62.51M
Net Cash€117.40M
Net Cash Per Share€9.66
Tangible Book Value Per Share€9.87
Margins
Gross margin is 27.04%, with operating margin of 9.71%, and net profit margin of 4.99%.
Gross Margin27.04%
Operating Margin9.71%
Pretax Margin6.96%
Net Profit Margin4.99%
EBITDA Margin15.20%
EBIT Margin8.45%
Analyst Forecast
The average price target for STRATEC Biomedical is €38.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€38.00
Price Target Upside56.38% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―